Investments Canceled: Expert Sees 'Clear Warning Shots' for German Pharma Sector

Germany's pharmaceutical sector is facing significant challenges, with major players like Boehringer Ingelheim and Eli Lilly scaling back or canceling substantial investments. Jasmina Kirchhoff, a pharmaceutical expert at the Institute of the German Economy (IW), described these moves as "clear warning shots" that signal fundamental issues with Germany as an investment location.

“

My assessment at this point would be that we are dealing with clear warning shots.

Boehringer Ingelheim announced it would not invest its planned 900 million euros in German sites between 2027 and 2030. Shortly after, U.S. giant Eli Lilly stated it would invest only half of its planned 2.5 billion dollars in a new facility in Alzey. Kirchhoff indicated that many other companies are likely considering similar decisions.

Kirchhoff pointed to Germany's proposed health reforms, particularly the "GKV-Beitragsstabilisierungsgesetz," as a major concern. She explained that these reforms are being discussed amid global shifts in market conditions, with the U.S. market restructuring and increasing pressure from Asia. The pharmaceutical industry is particularly critical of proposed dynamic manufacturer rebates, which they argue make long-term planning nearly impossible due to annual changes and expected increases.

“

What we are seeing right now is quite serious because these are considerations that many other companies will also be asking themselves.

Furthermore, the proposed law includes provisions for rebate contracts on innovative medicines, which the industry fears could undermine intellectual property rights. Kirchhoff contrasted Germany's approach with that of other countries, some of which have raised drug prices in response to U.S. policies. "What we are doing is exactly the opposite," she stated.

“

With them, it is practically no longer possible to make any plans at all, because these discounts change every year.

Kirchhoff expressed hope that German policymakers now recognize the serious conflict between health and economic objectives. She urged all relevant ministries to collaborate on solutions and stressed that Germany's actions have significant implications. As Europe's largest health market, Germany's pricing decisions influence other countries, and its pharmaceutical industry holds a strong international standing. "What we do here also has a signaling effect in other countries," she warned.

“

What we are doing is exactly the opposite.